Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.26 USD | +3.40% | +16.33% | -23.61% |
04-15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
03-25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.61% | 2.17B | |
+29.05% | 42.68B | |
-3.02% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.45% | 24.94B | |
-20.71% | 18.96B | |
+28.63% | 12.3B | |
-2.34% | 11.95B | |
-1.53% | 11.55B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Piper Sandler Adjusts Price Target on Intellia Therapeutics to $163 From $171, Reiterates Overweight Rating